tiprankstipranks
Alkermes plc (ALKS)
NASDAQ:ALKS
US Market
ALKS
Alkermes
RESEARCH TOOLSreports
Want to see ALKS full AI Analyst Report?

Alkermes (ALKS) Stock Forecast & Price Target

631 Followers
See the Price Targets and Ratings of:

ALKS Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
9 Buy
1 Hold
1 Sell
Based on 11 analysts giving stock ratings to
Alkermes
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$52.64
▲(52.44% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $52.64 with a high forecast of $65.00 and a low forecast of $38.00. The average price target represents a 52.44% change from the last price of $34.53.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","66":"$66","35.25":"$35.3","45.5":"$45.5","55.75":"$55.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.63636363636363,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,35.25,45.5,55.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.72,52.74153846153846,53.76307692307692,54.784615384615385,55.80615384615385,56.82769230769231,57.84923076923077,58.87076923076923,59.892307692307696,60.91384615384615,61.93538461538462,62.956923076923076,63.97846153846154,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.72,51.79048951048951,51.860979020979016,51.93146853146853,52.00195804195804,52.07244755244755,52.14293706293706,52.213426573426574,52.28391608391608,52.35440559440559,52.4248951048951,52.495384615384616,52.565874125874124,{"y":52.63636363636363,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.72,50.66461538461538,49.60923076923077,48.55384615384615,47.49846153846154,46.44307692307692,45.387692307692305,44.332307692307694,43.276923076923076,42.22153846153846,41.16615384615385,40.11076923076923,39.05538461538461,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.985,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.27,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$65.00Average Price Target$52.64Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on ALKS
Uy Ear
Mizuho Securities
Mizuho Securities
$53.78→$65
Buy
88.24%
Upside
Reiterated
07/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (NASDAQ: EOLS), Alkermes (NASDAQ: ALKS) and VolitionRX (NYSE MKT: VNRX)
Jefferies Analyst forecast on ALKS
Akash Tewari
Jefferies
Jefferies
$59→$65
Buy
88.24%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS) and Immunome (NASDAQ: IMNM)
RBC Capital Analyst forecast on ALKS
Leonid Timashev
RBC Capital
RBC Capital
$56
Buy
62.18%
Upside
Reiterated
07/07/26
Alkermes (ALKS) Gets a Buy from RBC Capital
Bank of America Securities Analyst forecast on ALKS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$38
Sell
10.05%
Upside
Downgraded
06/29/26
Alkermes downgraded to Underperform from Neutral at BofAAlkermes downgraded to Underperform from Neutral at BofA
Wells Fargo Analyst forecast on ALKS
Benjamin Burnett
Wells Fargo
Wells Fargo
$44→$65
Buy
88.24%
Upside
Assigned
06/29/26
Wells Fargo Keeps Their Buy Rating on Alkermes (ALKS)
Needham Analyst forecast on ALKS
Ami Fadia
Needham
Needham
$54→$61
Buy
76.66%
Upside
Assigned
06/24/26
Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK) and Alkermes (NASDAQ: ALKS)
TD Cowen Analyst forecast on ALKS
Joseph Thome
TD Cowen
TD Cowen
$42→$50
Buy
44.80%
Upside
Assigned
06/22/26
Alkermes Elevated to $50 Price Target as Orexin Leadership and Alixorexton Pipeline Drive Buy Rating
Piper Sandler Analyst forecast on ALKS
David Amsellem
Piper Sandler
Piper Sandler
$43
Buy
24.53%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Regeneron (NASDAQ: REGN) and Alkermes (NASDAQ: ALKS)
H.C. Wainwright Analyst forecast on ALKS
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$43
Hold
24.53%
Upside
Reiterated
06/18/26
Alkermes Price Target Reaffirmed at $43 as Encouraging Vibrance-2 Data Support Neutral Stance
Stifel Nicolaus Analyst forecast on ALKS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$42→$45
Buy
30.32%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Medline (NASDAQ: MDLN), Aclaris Therapeutics (NASDAQ: ACRS) and Alkermes (NASDAQ: ALKS)
UBS Analyst forecast on ALKS
Ashwani Verma
UBS
UBS
$42→$48
Buy
39.01%
Upside
Reiterated
05/06/26
Alkermes price target raised to $48 from $42 at UBSAlkermes price target raised to $48 from $42 at UBS
Leerink Partners Analyst forecast on ALKS
Marc Goodman
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
03/31/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on ALKS
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$43
Buy
24.53%
Upside
Reiterated
03/11/26
Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)
Truist Financial Analyst forecast on ALKS
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on ALKS
Rudy Li
Wolfe Research
Wolfe Research
$45
Buy
30.32%
Upside
Initiated
02/23/26
Alkermes initiated with an Outperform at Wolfe ResearchAlkermes initiated with an Outperform at Wolfe Research
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on ALKS
Uy Ear
Mizuho Securities
Mizuho Securities
$53.78→$65
Buy
88.24%
Upside
Reiterated
07/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (NASDAQ: EOLS), Alkermes (NASDAQ: ALKS) and VolitionRX (NYSE MKT: VNRX)
Jefferies Analyst forecast on ALKS
Akash Tewari
Jefferies
Jefferies
$59→$65
Buy
88.24%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS) and Immunome (NASDAQ: IMNM)
RBC Capital Analyst forecast on ALKS
Leonid Timashev
RBC Capital
RBC Capital
$56
Buy
62.18%
Upside
Reiterated
07/07/26
Alkermes (ALKS) Gets a Buy from RBC Capital
Bank of America Securities Analyst forecast on ALKS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$38
Sell
10.05%
Upside
Downgraded
06/29/26
Alkermes downgraded to Underperform from Neutral at BofAAlkermes downgraded to Underperform from Neutral at BofA
Wells Fargo Analyst forecast on ALKS
Benjamin Burnett
Wells Fargo
Wells Fargo
$44→$65
Buy
88.24%
Upside
Assigned
06/29/26
Wells Fargo Keeps Their Buy Rating on Alkermes (ALKS)
Needham Analyst forecast on ALKS
Ami Fadia
Needham
Needham
$54→$61
Buy
76.66%
Upside
Assigned
06/24/26
Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK) and Alkermes (NASDAQ: ALKS)
TD Cowen Analyst forecast on ALKS
Joseph Thome
TD Cowen
TD Cowen
$42→$50
Buy
44.80%
Upside
Assigned
06/22/26
Alkermes Elevated to $50 Price Target as Orexin Leadership and Alixorexton Pipeline Drive Buy Rating
Piper Sandler Analyst forecast on ALKS
David Amsellem
Piper Sandler
Piper Sandler
$43
Buy
24.53%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Regeneron (NASDAQ: REGN) and Alkermes (NASDAQ: ALKS)
H.C. Wainwright Analyst forecast on ALKS
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$43
Hold
24.53%
Upside
Reiterated
06/18/26
Alkermes Price Target Reaffirmed at $43 as Encouraging Vibrance-2 Data Support Neutral Stance
Stifel Nicolaus Analyst forecast on ALKS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$42→$45
Buy
30.32%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Medline (NASDAQ: MDLN), Aclaris Therapeutics (NASDAQ: ACRS) and Alkermes (NASDAQ: ALKS)
UBS Analyst forecast on ALKS
Ashwani Verma
UBS
UBS
$42→$48
Buy
39.01%
Upside
Reiterated
05/06/26
Alkermes price target raised to $48 from $42 at UBSAlkermes price target raised to $48 from $42 at UBS
Leerink Partners Analyst forecast on ALKS
Marc Goodman
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
03/31/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on ALKS
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$43
Buy
24.53%
Upside
Reiterated
03/11/26
Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)
Truist Financial Analyst forecast on ALKS
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on ALKS
Rudy Li
Wolfe Research
Wolfe Research
$45
Buy
30.32%
Upside
Initiated
02/23/26
Alkermes initiated with an Outperform at Wolfe ResearchAlkermes initiated with an Outperform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

3 Months
Ami FadiaNeedham
Success Rate
8/9 ratings generated profit
89%
Average Return
+19.68%
Copying Ami Fadia's trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +19.68% per trade.
1 Year
Ami FadiaNeedham
Success Rate
9/9 ratings generated profit
100%
Average Return
+57.71%
Copying Ami Fadia's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +57.71% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
18/18 ratings generated profit
100%
Average Return
+67.68%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +67.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
4
4
3
1
0
Buy
13
16
21
31
29
Hold
4
5
4
4
3
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
21
25
28
37
33
In the current month, ALKS has received 29 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. ALKS average Analyst price target in the past 3 months is 52.64.
Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is -$0.02 with a range of -$0.18 to $0.25. The previous quarter’s EPS was -$0.40. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.
Next quarter’s earnings estimate for ALKS is -$0.02 with a range of -$0.18 to $0.25. The previous quarter’s EPS was -$0.40. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $458.78M with a range of $435.89M to $488.40M. The previous quarter’s sales results were $392.91M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.
Next quarter’s sales forecast for ALKS is $458.78M with a range of $435.89M to $488.40M. The previous quarter’s sales results were $392.91M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?
Based on analyst ratings, Alkermes plc’s 12-month average price target is 52.64.
    What is ALKS’s upside potential, based on the analysts’ average price target?
    Alkermes plc has 52.44% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALKS a Buy, Sell or Hold?
          Alkermes plc has a consensus rating of Moderate Buy which is based on 9 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Alkermes plc’s price target?
            The average price target for Alkermes plc is 52.64. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $65.00 ,the lowest forecast is $38.00. The average price target represents 52.44% Increase from the current price of $34.53.
              What do analysts say about Alkermes plc?
              Alkermes plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of ALKS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.